Scribe Therapeutics Inc. (NASDAQ:SCTX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a moderately bullish view: Five brokerages rate Scribe Therapeutics “Moderate Buy,” with four buys and one hold. The average 12-month price target is $51.75, including targets of $50 to $60 from recent coverage.
• Clinical and financial progress strengthened the outlook: Scribe reported a second-quarter loss of $3.84 per share, beating the expected $6.20 loss, and began a first-in-human Phase 1 trial of its STX-1150 cholesterol-lowering therapy.
• Funding extends the company’s runway, but risks remain: More than $25 million in grants and roughly $155.5 million from an IPO and Sanofi private placement are expected to fund operations into the first half of 2029. However, Scribe remains unprofitable, and continued spending and equity issuance could create dilution and volatility.

Scribe Therapeutics Inc. (NASDAQ:SCTX - Get Free Report) has earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $51.75.

Several analysts recently commented on SCTX shares. Zacks Research upgraded Scribe Therapeutics to a "hold" rating in a research report on Tuesday. Wall Street Zen raised Scribe Therapeutics to a "hold" rating in a report on Saturday, August 1st. HC Wainwright initiated coverage on shares of Scribe Therapeutics in a research note on Monday. They set a "buy" rating and a $60.00 price objective on the stock. Guggenheim initiated coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an "overweight" rating and a $60.00 target price for the company.

More Scribe Therapeutics News

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
• Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
• Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
• Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
• Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
• Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.

Insider Activity at Scribe Therapeutics

In related news, Director Carl L. Gordon purchased 1,000,000 shares of Scribe Therapeutics stock in a transaction dated Monday, July 27th. The stock was bought at an average cost of $15.00 per share, with a total value of $15,000,000.00. Following the purchase, the director owned 1,348,825 shares in the company, valued at approximately $20,232,375. The trade was a 286.68% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO David Parrot acquired 2,666 shares of the firm's stock in a transaction dated Thursday, July 23rd. The stock was bought at an average price of $15.00 per share, with a total value of $39,990.00. Following the completion of the acquisition, the chief financial officer directly owned 1,333 shares of the company's stock, valued at approximately $19,995. This represents a -200.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 3,727,237 shares of company stock valued at $56,291,746.

Scribe Therapeutics Stock Performance

Shares of SCTX opened at $30.90 on Thursday. Scribe Therapeutics has a 1 year low of $17.31 and a 1 year high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) last released its quarterly earnings results on Wednesday, September 2nd. The company reported ($3.84) earnings per share for the quarter, beating analysts' consensus estimates of ($6.20) by $2.36. As a group, sell-side analysts expect that Scribe Therapeutics will post -6.72 EPS for the current fiscal year.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source